Compare TDOC & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | AVLN |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2026 |
| Metric | TDOC | AVLN |
|---|---|---|
| Price | $8.30 | $30.02 |
| Analyst Decision | Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $7.56 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 321.4K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $28.26 |
| 52 Week High | $9.77 | $33.24 |
| Indicator | TDOC | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | N/A |
| Support Level | $7.97 | N/A |
| Resistance Level | $9.70 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 95.94 | 0.00 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.